MHRA Confirms Registration of Avacta's AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Avacta Group plc (AIM: AVCT), the developer of diagnostics and innovative cancer therapies based on its ...

The test was developed after the researchers ... More information: Richard Willson et al, Development of a rapid antigen-based lateral flow assay for tick-borne spotted fever rickettsioses ...

New research shows that at-home prostate cancer tests are producing inconsistent and inaccurate results. Read on for more!